hCAII-IN-9 NEW
Price | $68 | $148 | $215 |
Package | 1mg | 5mg | 10mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-15 |
Product Details
Product Name: hCAII-IN-9 | CAS No.: 2878477-18-8 |
Purity: 98.63% | Supply Ability: 10g |
Release date: 2024/11/15 |
Product Introduction
Bioactivity
名稱 | hCAII-IN-9 |
描述 | hCAII-IN-9 is a potent carbonic anhydrase inhibitor with IC50 values of 1.18 μM for hCA II, 0.17 μM for hCA IX, and 2.99 μM for hCA XII. It is not blood-brain barrier permeable. |
體外活性 | HCAII-IN-9 (Compound 11) (100 μM; 24-48 h) inhibits BHK-21 and HEK-293 cells with cell viability of 48% and 72%, respectively.[1] |
存儲條件 | Shipping with blue ice. |
溶解度 | DMSO : 55 mg/mL (131.61 mM) |
相關產品 | Benzenesulfonamide | Urea | Topiramate | Cyclamic acid sodium | Ellagic acid | Orthanilamide | Tioxolone | Zonisamide | Histone acetyltransferase p300 Inhibitor 4c | EMAC10101d | pNNP | Trichlormethiazide |
相關庫 | 經典已知活性庫 | 抑制劑庫 | 已知活性化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$2500.00/100mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
$0.00/10mg |
VIP1Y
|
ShenZhen H&D Pharmaceutical Technology Co., LTD
|
2024-08-07 |
- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY